Close



Nov 7, 2023 04:05PM
Jul 26, 2023 09:00PM
Jul 21, 2023 09:00PM
Jul 16, 2023 09:00PM
Jul 10, 2023 09:39PM
Jul 5, 2023 09:00PM
Jun 6, 2023 08:07AM Zai Lab (ZLAB) and Novocure (NVCR) Report LUNAR Phase 3 Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival
Jun 6, 2023 08:05AM
Apr 27, 2023 07:32AM
Apr 27, 2023 07:30AM
Mar 20, 2023 06:35AM
Mar 1, 2023 04:01PM
Feb 22, 2023 07:30AM
Feb 22, 2023 07:30AM Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
Jan 30, 2023 07:30AM
Jan 30, 2023 07:30AM
Jan 5, 2023 07:35AM
Jan 5, 2023 07:34AM
Nov 9, 2022 04:01PM
Nov 8, 2022 07:30AM
Sep 27, 2022 08:03AM Zai Lab Limited (ZLAB) and Seagen (SGEN) Enter Collaboration and License Agreement for TIVDAK
Sep 27, 2022 08:00AM
Sep 27, 2022 08:00AM
Aug 9, 2022 04:05PM
Aug 8, 2022 07:12AM
Aug 8, 2022 07:02AM
Jul 13, 2022 07:30AM
Jul 13, 2022 07:30AM Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis
Jun 10, 2022 07:30AM
Jun 10, 2022 07:30AM
May 10, 2022 04:01PM
Apr 28, 2022 07:31AM
Apr 28, 2022 07:30AM
Apr 28, 2022 07:30AM
Mar 1, 2022 04:05PM Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021
Jan 6, 2022 07:36AM
Jan 6, 2022 07:30AM
Dec 20, 2021 06:30AM
Dec 17, 2021 06:09PM
Dec 16, 2021 11:57AM
Dec 16, 2021 11:36AM
Dec 16, 2021 04:43AM China NMPA Approves NUZYRA® as a Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (AB
Nov 9, 2021 04:10PM
Nov 9, 2021 07:37AM
Oct 4, 2021 09:10AM
Aug 9, 2021 04:30PM
Jul 7, 2021 08:38AM
May 28, 2021 07:30AM
May 28, 2021 07:30AM Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib
May 10, 2021 07:32AM

239,998 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All